Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 6;8(2):286-307.
doi: 10.1021/acsptsci.4c00663. eCollection 2025 Feb 14.

A Comprehensive Review of Current Approaches in Bladder Cancer Treatment

Affiliations
Review

A Comprehensive Review of Current Approaches in Bladder Cancer Treatment

Soniya Kumbham et al. ACS Pharmacol Transl Sci. .

Abstract

Bladder cancer is one of the most common malignant tumors of the urinary system globally. It is also one of the most expensive cancers to manage, due to the need for extensive treatment and follow-ups that often involve invasive and costly procedures. Although there have been some improvements in treatment options, the quality of life they offer has not improved at the same rate as other cancers. Therefore, there is an urgent need to find new alternatives to ease the burden of bladder cancer on patients. Recent discoveries have opened new avenues for the diagnosis and management of bladder cancer even though the clinical approach has largely remained the same for years. The decline in bladder cancer-specific mortality in regions that promote social awareness of risk factors and reduction of carcinogenic exposure demonstrates the effectiveness of such measures. New agents have been approved for patients who have undergone radical cystectomy after Bacillus Calmette-Guérin failure. Current best practices for diagnosing and treating bladder cancer are presented in this review. The review discusses radiation therapy, photodynamic therapy, gene therapy, chemotherapy, and nanomedicine in relation to non muscle-invasive cancers and muscle-invasive bladder cancers, as well as systemic treatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

References

    1. Ferlay J. E. M.; Lam F.; Colombet M.; Mery L.; Piñeros M.; Znaor A.; Soerjomataram I.; Bray F.. Global Cancer Observatory: Cancer Today; Lyon, Fr. Int. Agency Res. Cancer, 2018.
    1. Siegel R. L.; Giaquinto A. N.; Jemal A. Cancer Statistics, 2024. CA. Cancer J. Clin. 2024, 74 (1), 12–49. 10.3322/caac.21820. - DOI - PubMed
    1. Martin J. W.; Carballido E. M.; Ahmed A.; Farhan B.; Dutta R.; Smith C.; Youssef R. F. Squamous Cell Carcinoma of the Urinary Bladder: Systematic Review of Clinical Characteristics and Therapeutic Approaches. Arab J. Urol. 2016, 14 (3), 183–191. 10.1016/j.aju.2016.07.001. - DOI - PMC - PubMed
    1. Bogen J. P.; Grzeschik J.; Jakobsen J.; Bähre A.; Hock B.; Kolmar H. Treating Bladder Cancer: Engineering of Current and next Generation Antibody-, Fusion Protein-, MRNA-, Cell-and Viral-Based Therapeutics. Front. Oncol. 2021, 11, 67226210.3389/fonc.2021.672262. - DOI - PMC - PubMed
    1. Babjuk M.; Burger M.; Compérat E. M.; Gontero P.; Mostafid A. H.; Palou J.; van Rhijn B. W. G.; Rouprêt M.; Shariat S. F.; Sylvester R. European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and Carcinoma in Situ)-2019 Update. Eur. Urol. 2019, 76 (5), 639–657. 10.1016/j.eururo.2019.08.016. - DOI - PubMed